A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Autologous cultured kidney tissue cells (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors RegenMedTX
- 18 Apr 2019 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 07 Jun 2018 Status changed from not yet recruiting to recruiting.
- 03 Mar 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.